Regentis Biomaterials Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	May '26 May 8, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Debt / Equity Ratio	0.25	0.25	-
Debt / EBITDA Ratio	-0.17	-0.17	-
Net Debt / Equity Ratio	-1.30	-1.30	-
Net Debt / EBITDA Ratio	0.89	0.89	-
Quick Ratio	2.57	2.57	-
Current Ratio	2.65	2.65	-
Return on Equity (ROE)	-575.38%	-575.38%	-
Return on Assets (ROA)	-182.94%	-182.94%	-
Return on Invested Capital (ROIC)	969.80%	969.80%	-
Return on Capital Employed (ROCE)	-293.76%	-293.76%	-
Buyback Yield / Dilution	-249.41%	79.51%	-
Total Shareholder Return	-249.41%	79.51%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q